WA-NURIFLEX/LINE-PLUS
27.5.2021 15:02:13 CEST | Business Wire | Press release
NuriFlex Inc. (“NuriFlex ”) announced that it has signed a memorandum of understanding (“MoU ”) with LINE Plus Corporation (“LINE ”), and the two companies intend to collaborate in the Central Bank Digital Currency (“CBDC ”) platform business in various regions, including but not limited to the Caribbean, South America and Africa.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210527005334/en/
One of NuriFlex’s business specialties involves the design and development of a blockchain-based platform to offer digital payment and other services for various industry sectors. NuriFlex is currently participating as a main technical partner for the national health coverage system in Cameroon, known as the UHC Project, and it is in several discussions with other partners in Africa to launch other services based on blockchain technologies.
For the last 20 years, NuriFlex Group has focused on the development of a software platform capable of processing a large volume of data, and implemented such a platform to global utility companies. Combining these experiences with blockchain technology, NuriFlex intends to work with a very reputable global partner, LINE Plus Corporation, on global CBDC projects that require a platform that can handle vast volumes of data.
LINE Plus Corporation, the Korea-based subsidiary of LINE Corporation leading LINE’s global business development, has been researching, developing, and operating blockchain-related services including a CBDC blockchain platform with a dedicated blockchain engineering team. Based on LINE Blockchain technology and experience in participating CBDC projects, LINE aims to provide a blockchain platform solution that is the right fit for each CBDC project.
“We are excited to partner and collaborate with LINE on CBDC Projects. The blockchain technology experience and business development capabilities that NuriFlex and LINE bring together will be a great advantage to successfully accomplish CBDC business opportunities,” said Elizabeth Park, Chief Executive Officer of NuriFlex Inc.
“With NuriFlex’s business experience in the region and LINE’s blockchain technology, we hope to bring financial innovation in the Caribbean, South America and Africa with a CBDC blockchain platform,” said Hongkyu Lee, Lead of Blockchain Lab at LINE Plus Corporation.
About NuriFlex Inc.
NuriFlex Inc. is a digital transformation company that provides convergent solutions to address poor efficiency and improve transactional yields in various industries. NuriFlex Inc. offers robust and reliable products and services based on its core telecommunication & blockchain technologies. Learn more at www.nuriflex.com .
About LINE Plus Corporation
LINE Plus Corporation was established in March 2013 in South Korea as a subsidiary of LINE Corporation. It supports LINE’s global business development with programmers, designers, marketers, sales personnel and PR managers from around the world working together.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005334/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kiabi Selects Navan to Centralise Global Travel Program11.5.2026 09:00:00 CEST | Press release
Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Kiabi, the French multinational fashion retailer, to consolidate its global travel with one unified platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511547434/en/ Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform To support its workforce of nearly 10,000 “Kiabers,” the retailer required a solution capable of providing an easy-to-use travel platform. Navan was selected due to its intuitive AI-powered interface and ability to integrate with Kiabi’s travel policies directly in-app. “Managing travel was becoming an administrative burden that slowed our teams down,” said Denise Maurice, Indirect Procurement Director at Kiabi. “We wanted to give our ‘Kiabers’ the
Owl Labs partners with Westcoast to expand access to seamless hybrid meeting experiences in the UK and Ireland11.5.2026 09:00:00 CEST | Press release
Partnership aims to reduce the ‘meeting tax’ by expanding access to Owl Labs products through Westcoast’s extensive distribution network Owl Labs, a global leader in AI-powered, 360-degree video conferencing solutions, today announced a new UK and Ireland distribution partnership with Westcoast Limited, one of the country’s largest and most trusted IT distributors. The agreement will see Westcoast distribute the full range of Owl Labs’ award-winning Meeting Owl and Owl Bar products across the UK and Ireland, providing greater choice, availability, and dedicated support for resellers and end customers navigating the demands of hybrid work. The partnership aims to address the technical setup challenges that plague meetings across the UK. Owl Labs’ recent State of Hybrid Work report found that nearly 8 in 10 workers (79%) lose time in meetings due to technical difficulties such as connecting to a meeting or setting up a camera. By making Owl Labs’ solutions simpler to source, deploy and s
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay11.5.2026 09:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). “With Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma now CE‑marked on our LUMIPULSE G platform, we are advancing a new era of neurology diagnostics—one where blood‑based biomarkers enable earlier, broader, and more accessible insights into Alzheimer’s disease and neurodegeneration.” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “By delivering fully automated and scalable solutions, we are helping clinicians move decisively toward more timely and informed decision‑making. This milestone underscores our long‑term vision to reimagine the diagnostic
Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 202611.5.2026 08:00:00 CEST | Press release
The MEVION S250-FIT™ creates a new pathway for European cancer centers to integrate proton therapy into existing radiotherapy programs Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507172087/en/ The MEVION S250-FIT™ Proton Therapy System Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatment environments, aligning advanced proton capability with the infrastructure, workflows, and capital planning of modern radiation oncology. Stanford Medicine: First S250-FIT Installation On April 7, 2026, Stanford Medicine unveiled
Vedanta FY26 Profit Soars by 22% to $2.8 bn; Enters Demerger Phase11.5.2026 02:30:00 CEST | Press release
India-based Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals, oil & gas, critical minerals, power and technology, announced its results for the fourth quarter and full year ended 31 March 2026. It has delivered its best-ever financial performance, driven by structurally strong businesses and disciplined execution. For the full year, Vedanta’s Profit stood at an all-time high of $2.8 bn, reflecting a 22% YoY increase and a profit of $1 bn in Q4 FY26, up nearly 90% YoY. Vedanta reported its highest-ever annual revenue of about $20 bn, up 15% YoY, with Q4 revenue at $5.6 bn, an increase of nearly 30% YoY. The Company maintained strong cost leadership, contributing to record EBITDA of $6.3 bn for FY26, up by about 30% YoY, with margins expanding to around 40%. Q4 EBITDA stood at $2.0 bn, up by nearly 60% YoY, with a margin of approximately 44%. The balance sheet strengthened further, with Net Debt/EBITDA improving to 0.95x, supported by strong cash generation. Underscor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom